Microsoft word - factsheet_march2008final.doc

The Ultimate Polymer Delivery System. Invisible Action… Visible Results!™ CONTACTS & KEY INFORMATION

Headquarters
SKINVISIBLE IS A DRUG-DELIVERY COMPANY THAT OUT-LICENSES ITS INVISICARE®
FAMILY OF POLYMER DELIVERY VEHICLES which, when topically applied, hold their active
ingredients on the skin for up to four hours thereby affording the active agents an extended time- frame to perform their intended functions. The Company’s superior polymer Symbol ‘SKVI’
delivery platforms are designed to significantly enhance product performance for established Website - Corp
brand manufacturers of prescription, as well as over-the-counter (OTC), dermatological, - Product www.invisicare.com
medical, cosmetic and skincare products. Out. Shares
Public Float
►TYPICALLY, SKINVISIBLE’S LICENSING AGREEMENTS INCLUDE EXCLUSIVITY FOR A
Inside Owners 45%
SPECIFIED TOPICAL SKIN APPLICATION WITHIN A DEFINED TERRITORY. Skinvisible licenses
Topical drug delivery technology its patented technology to established developers and manufacturers of dermatological, medical, cosmetic and skincare products, thereby granting them the right to incorporate Invisicare® polymer delivery vehicles into identified product formulations. Under these agreements, Skinvisible receives a license fee upfront and ongoing royalty payments on
MANAGEMENT TEAM
Terry Howlett
►THE NUCLEUS OF SKINVISIBLE’S INVISICARE® FAMILY OF POLYMER DELIVERY VEHICLES IS
ITS FORMULA AND PROCESS FOR COMBINING HYDROPHILIC AND HYDROPHOBIC POLYMERS
Dr. James A. Roszell
INTO STABLE COMPLEXES IN WATER EMULSIONS. This allows formulated products using
Vice President, Research and Development Invisicare® as their platform to remain on the skin for extended periods of time, resulting in Teresa Petraia
improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. Skinvisible’s process for combining water-soluble and insoluble polymers is specifically formulated to carry water-insoluble active ingredients in water-based products SELECTED RECENT NEWS
without the use of alcohol, silicones, waxes, or other organic solvents. Products utilizing Invisicare® have the proven ability to bond active ingredients to the skin for up to four or Breaking News: 01/30/2008: Skinvisible®
more hours. They are non-occlusive and allow normal skin respiration and perspiration Announces Licensing Agreement for
while moisturizing the skin and forming a protective bond, resisting wash-off, and delivering Adapalene – The Company’s First Acne
targeted levels of therapeutic or cosmetic skincare agents to the skin. The invisible polymer Product Enter the $2.8 Billion Worldwide
compositions wear off as part of the natural exfoliation process of the skin’s outer layer of Market LAS VEGAS, Nevada. January 30, 2008 – Skinvisible,
Inc. (OTCBB: SKVI / Website: www.skinvisible.com), a research and cells. development company focused on formulating and enhancing patented dermatology products with their proprietary polymer PRODUCTS
delivery system Invisicare®, announced it has signed an exclusive licensing agreement with Panalab Internacional S.A. (“Panalab”). The Agreement is for the right to develop and commercialize Skinvisible has developed a patented technology and trade Skinvisible’s prescription anti-acne products formulated with marked its associated family of polymer delivery vehicles under adapalene and Invisicare® in Argentina, Brazil and Chile. the name Invisicare®. The Invisicare® product family offers Under the terms of the agreement Panalab, a multi-national five distinctive polymer formulations that hold active dermatology company headquartered in Panama with subsidiaries and partners in most Latin American countries wil be responsible for filing and obtaining marketing approval in the countries they have licensed. While al terms of the agreement were not disclosed, Licensed Technology / Invisicare® Polymer Delivery Vehicles
Skinvisible will receive a research and development fee plus Skinvisible licenses its patented technology to established milestone payments. In addition the Company will receive royalties developers and manufacturers of dermatological, medical, based on revenues generated by the sale of the products. According to the agreement, Panalab will have the right to cosmetic and skincare products, thereby granting them the right manufacture, distribute, market, sel and promote the adapalene to incorporate Invisicare® polymer delivery vehicles into formulations in the specified territory. “We are very pleased to sign this agreement with Panalab brought to us by Riley-Nacht, LLC, one of our pharmaceutical consulting Pipeline of Products Available for Licensing
firms representing our products and technology to international pharmaceutical and cosmeceutical companies,” said Mr. Ter y Howlett, President/CEO of Skinvisible. “The acne market is extremely large, with retinoids like adapalene making up the largest portion with over 60% market share. We are entering the acne market with adapalene as it is the market leader and we are confident that dermatology companies will be interested in obtaining the rights to our Invisicare® formulations incorporating adapalene, especially with our ability to seek patent protection for these

Source: http://www.skinvisible.com/pdf/fact_sheet.pdf